Concepedia

Hugh D. Falls

HD

15

Publications

798

Citations

13

H-Index

2002

Active since

Affiliations

Abbott Fund(Current)

AbbVie (United States)

Abbott (United Kingdom)

BioPAL (United States)

Olivia Newton-John Cancer Wellness & Research Centre

Hugh D. Falls is an author at Abbott Fund specializing in medicine, pharmacology, and pharmacotherapy.

Top concepts

MedicinePharmacologyPharmacotherapyBiochemistryPhysiologyEndocrinologyDrug DiscoveryGliomaImmunologyTumor Biology

Publications per year

2002–2021

15

Publications

15

Protein tyrosine phosphatase 1B negatively regulates leptin signaling in a hypothalamic cell line

Wiweka Kaszubska, Hugh D. Falls, Verlyn G. Schaefer et al. · Molecular and Cellular Endocrinology · 2002 · 185 citations

Hypothalamic Cell Line, Developmental Biology, Signal Transduction +12

ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope

Andrew C. Phillips, Erwin R. Boghaert, Kedar S. Vaidya et al. · Molecular Cancer Therapeutics · 2016 · 175 citations · Full text

Tumor Biology, Drug Targeting, Tumor-selective Egfr Epitope +15

Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody

Edward B. Reilly, Andrew C. Phillips, Fritz G. Buchanan et al. · Molecular Cancer Therapeutics · 2015 · 79 citations

Immunology, Pathology, Glioma +16

Discovery and Pharmacological Evaluation of Growth Hormone Secretagogue Receptor Antagonists

Zhili Xin, Michael D. Serby, Hongyu Zhao et al. · Journal of Medicinal Chemistry · 2006 · 50 citations · Full text

Medicinal Chemistry, Growth Hormone, Pharmacological Study +14

Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate

Andrew C. Phillips, Erwin R. Boghaert, Kedar S. Vaidya et al. · Molecular Cancer Therapeutics · 2018 · 48 citations · Full text

Rows per page

1–5 of 15